Opus Genetics, Inc. (IRD) Misses Q3 EPS by 4c

Opus Genetics, Inc. (NASDAQ: IRD) reported Q3 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.87 million versus the consensus estimate of $2.28 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Eos Energy Enterprises (EOSE) PT Lowered to $5 at B.Riley